This article needs additional citations for
verification. (January 2021) |
Clinical data | |
---|---|
Trade names | Dipentum |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a601088 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 99% |
Elimination half-life | 0.9 hours |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.116.494 |
Chemical and physical data | |
Formula | C14H10N2O6 |
Molar mass | 302.242 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Olsalazine is an anti-inflammatory medication used in the treatment of ulcerative colitis. [2] [3] It is sold under the brand name Dipentum. [4]
Olsalazine itself is a pro-drug of mesalazine (5-aminosalicyclic acid or 5-ASA) and is not absorbed in the small intestine. Instead it continues through to the colon where it is cleaved into two molecules of 5-ASA by azoreductases produced by colonic bacteria. Olsalazine thus exerts its anti-inflammatory effect by its colonic breakdown into 5-ASA which inhibits cyclooxygenase and lipoxygenase thereby reducing prostaglandin and leukotriene production. [4]
Olsalazine gained Food and Drug Administration (FDA) approval in 1990.
The drug is supplied by UCB Pharma.
In 2006 the Australian biotech company Giaconda received a European patent for a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti- gout drug colchicine, for trials the following year. [5]
This article needs additional citations for
verification. (January 2021) |
Clinical data | |
---|---|
Trade names | Dipentum |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a601088 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 99% |
Elimination half-life | 0.9 hours |
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.116.494 |
Chemical and physical data | |
Formula | C14H10N2O6 |
Molar mass | 302.242 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Olsalazine is an anti-inflammatory medication used in the treatment of ulcerative colitis. [2] [3] It is sold under the brand name Dipentum. [4]
Olsalazine itself is a pro-drug of mesalazine (5-aminosalicyclic acid or 5-ASA) and is not absorbed in the small intestine. Instead it continues through to the colon where it is cleaved into two molecules of 5-ASA by azoreductases produced by colonic bacteria. Olsalazine thus exerts its anti-inflammatory effect by its colonic breakdown into 5-ASA which inhibits cyclooxygenase and lipoxygenase thereby reducing prostaglandin and leukotriene production. [4]
Olsalazine gained Food and Drug Administration (FDA) approval in 1990.
The drug is supplied by UCB Pharma.
In 2006 the Australian biotech company Giaconda received a European patent for a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti- gout drug colchicine, for trials the following year. [5]